The Allele Discriminating Priming System (ADPS)
is the most precise cancer mutation diagnostic platform technology.
Analyze a first stage cancer patient’s ctDNA using liquid biopsy optimized for
precision medicine and companion diagnostics based on qPCR, easy and quick.
To improve detection sensitivity with no false positives,
we succeeded in the imposing challenge of adding the capability of discriminating mutations to DNA polymerase
which is directly involved in gene amplification.
Based on this, we developed ADPS™, a molecular diagnostic platform for cancer. ADPS™,
which is capable of being used in both tissue and liquid biopsies, supports more efficient precision medicine with
a maximum detection sensitivity of 0.0001%.
ADPS™ is a qPCR-based cancer diagnosis technology that precisely analyzes cancer genes with a detection sensitivity of up to 0.0001% (3/3,000,000).
The new ADPS™ smart DNA polymerase can distinguish between normal and mutant genes and amplifies only the mutant genes.
ADPS™ achieved a detection sensitivity of 0.01% without false positives by exclusively amplifying mutated DNAs while leaving the wild type intact.
A detection sensitivity of 0.01% to 1% is required to analyze ctDNA from the patients, but current liquid biopsy diagnostic technology fails to attain a detection sensitivity of 0.01%.
ADPS™ can be used during the full range of cancer treatment from prognosis, diagnosis, and prediction to treatment decision assistance, treatment monitoring, and relapse testing.
This page provides recently completed clinical trial results. Review the performance of ADPS™ and learn more about us.